Global Regulatory Harmonization: How Close Are We to a Common GMP Framework?

Key Takeaways

• ICH and PIC/S have created a substantial shared technical foundation for GMP, but national and regional legal implementation is not uniform.

• Post-approval manufacturing changes remain a major point of divergence, with separate EU and U.S. reporting frameworks and additional market-specific procedures.

• EU Qualified Person certification and U.S. quality-unit record review illustrate different legal responsibilities around batch disposition.

• Inspection mutual recognition has produced measurable reliance, including 157 EU inspections that FDA reported deferring by December 2019 after reviewing partner information.

• Manufacturers can combine consistent global quality processes with jurisdiction-specific regulatory planning, while authorities expand appropriate reliance and procedural alignment.

International efforts to harmonize pharmaceutical manufacturing requirements have produced substantial convergence in quality principles, good manufacturing practice (GMP) standards, and regulatory inspection practices. Through the International Council for Harmonisation (ICH), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and international regulatory cooperation, authorities have established increasingly consistent expectations for pharmaceutical quality. However, agreement on technical principles does not necessarily translate into uniform regulatory procedures, mutual recognition of inspections, or equivalent compliance obligations across markets. Differences in post-approval change management, manufacturing guidance, and batch certification continue to complicate multinational operations. Further progress may depend less on developing additional global standards than on achieving greater consistency in how existing requirements are implemented, recognized, and applied.

A pharmaceutical manufacturer seeking to improve an established production process for a medicine sold in the United States, Europe, and Japan faces a challenge that extends beyond demonstrating that the proposed change will preserve product quality. Even with a single scientific justification, the company must determine how the change should be classified, reported, and authorized in each market. Depending on its nature and the applicable regulatory requirements, the change may follow different procedures and implementation timelines. The manufacturing science may be consistent, but the regulatory pathways are not necessarily interchangeable.

This situation illustrates a persistent challenge in international pharmaceutical manufacturing. Decades of cooperation have produced increasingly consistent expectations for product quality, manufacturing controls, and regulatory oversight. ICH guidelines provide common scientific principles, PIC/S promotes harmonized GMP standards and inspection practices, and mutual recognition agreements (MRAs) allow certain regulatory authorities to rely on one another's inspection findings. These initiatives have established a substantial common foundation for pharmaceutical manufacturing quality

Harmonization takes several forms. Technical harmonization establishes shared expectations for how medicines should be developed, manufactured, and controlled. Inspection harmonization promotes consistency in how authorities assess compliance. Legal and operational harmonization concerns the procedures through which regulators authorize manufacturing changes, recognize inspection outcomes, certify batches, and oversee products within their jurisdictions.

Progress in these areas has not occurred at the same pace. Understanding where requirements have converged, and where important differences remain, is essential to understanding how much further global GMP harmonization can advance.

ICH and PIC/S have played complementary roles in establishing the international foundation for pharmaceutical manufacturing quality.

ICH develops harmonized scientific and technical guidelines intended to support the registration and regulation of pharmaceutical products across participating regions. Its quality guidelines address subjects ranging from stability studies and impurities to pharmaceutical development, manufacturing controls, and analytical procedures. Particularly important are ICH Q7, which addresses GMP for active pharmaceutical ingredients; Q8, which establishes principles for pharmaceutical development; Q9, which provides a framework for quality risk management; and Q10, which describes the pharmaceutical quality system.

These guidelines have helped establish an internationally shared approach to pharmaceutical quality based on scientific understanding, systematic risk management, and control throughout the product life cycle. More recent guidance extends these principles into post-approval change management under ICH Q12 and continuous manufacturing under ICH Q13.

However, adoption of an internationally agreed guideline does not automatically create identical regulatory requirements. ICH members implement guidelines through their respective national or regional frameworks, and the organization monitors differences in implementation and adherence. Authorities may therefore share a scientific position while retaining different legal mechanisms for applying it.¹

PIC/S addresses harmonization more directly through GMP standards and regulatory inspection systems. Established in 1995 as an extension of the earlier Pharmaceutical Inspection Convention, PIC/S is a nonbinding cooperative arrangement among regulatory authorities responsible for GMP oversight. It supports the development of common standards, consistent inspection procedures, inspector training, and cooperation among participating authorities.²

The close relationship between the PIC/S GMP Guide and the European Union (EU) GMP Guide illustrates the extent of technical convergence. In September 2026, PIC/S revised its GMP Guide to version PE 009-18, incorporating updated provisions in Annex 19 concerning reference and retention samples.³ The revision was coordinated with the corresponding EU update, and both entered into force on September 24, 2026. Authorities outside the European Economic Area (EEA) were invited to incorporate the revised annex into their national GMP guides.

The revision also demonstrates the boundaries of harmonization. Annex 19 includes provisions concerning samples associated with parallel-imported, parallel-distributed, and parallel-traded products, but their applicability depends on the relevant local legislation. Even closely aligned technical guidance may therefore operate differently under distinct legal frameworks.

PIC/S cooperation continues in other areas of manufacturing oversight. In July 2026, the organization published revised recommendations on qualification and validation, PI 006-4, which entered into force on October 1.⁴ The revisions were developed through a working group led at different stages by representatives of regulatory authorities in the United Kingdom, Ireland, and the United States, demonstrating continued international collaboration on manufacturing control and validation practices.

Membership in PIC/S does not, however, automatically require participating authorities to recognize one another's GMP certificates. Such obligations depend on separate legal arrangements, including applicable recognition agreements and participation in the Pharmaceutical Inspection Convention. Alignment of inspection standards can strengthen confidence in the work of other regulators, but formal recognition requires additional mechanisms.⁵

The practical limits of harmonization become clearest when manufacturers must translate shared technical principles into regulatory actions across different markets. Post-approval changes, sterile manufacturing controls, and batch certification illustrate how common quality objectives interact with jurisdiction-specific requirements.

Changes to an approved manufacturing process may involve equipment, process parameters, analytical methods, manufacturing sites, or elements of a product's control strategy. Although companies can evaluate the scientific and technical implications of these modifications within a common pharmaceutical quality system, the regulatory obligations governing implementation depend on the relevant markets.

ICH Q12 was developed to improve the predictability and efficiency of post-approval chemistry, manufacturing, and controls (CMC) changes.⁶ The guideline introduces tools intended to support more structured product life cycle management, including Established Conditions, which identify elements of an approved application considered necessary to assure product quality and subject to regulatory reporting when changed. It also establishes principles for determining the regulatory implications of changes based on scientific understanding and risk.

The EU's initial implementation of Q12 provides an example of the difficulties that arise when globally agreed guidance must operate within an existing regional legal framework.⁷ In March 2020, the European Commission acknowledged that several Q12 principles were compatible with EU requirements, but certain provisions could not be implemented with the full flexibility contemplated by the guideline. These included additional scientific risk-based approaches to defining Established Conditions and their reporting categories, as well as the Product Lifecycle Management document. The Commission attributed these limitations to differences between Q12 and the EU variations framework then in effect.

That framework has since evolved. A revised EU Variations Regulation became applicable on January 1, 2025, and updated Variations Guidelines took effect on January 15, 2026.⁸ The European Medicines Agency (EMA) also issued revised questions and answers on post-approval change management protocols (PACMPs), effective January 15, 2026, addressing their preparation, submission, and regulatory evaluation under the updated framework.⁹ These developments reflect continued refinement of EU change-management procedures, although they do not establish that every limitation identified in 2020 has been resolved.

Differences among regulatory reporting systems remain relevant to multinational manufacturers. In the EU, variations are classified through a system that includes Type IA changes, generally representing minor variations; Type IB changes, which follow a notification procedure before implementation; and Type II changes, which represent major variations requiring regulatory assessment. The applicable procedures depend on the classification and conditions associated with the proposed change.

The U.S. Food and Drug Administration (FDA) applies a different reporting structure under 21 CFR 314.70 for changes to approved new drug applications and abbreviated new drug applications.¹⁰ Depending on their potential impact, changes may require a prior approval supplement, a changes-being-effected supplement, or reporting in an annual report. Licensed biological products are subject to corresponding post-approval change requirements under 21 CFR 601.12, which likewise distinguishes changes according to their potential effects on product quality and safety.¹¹ These provisions determine the reporting pathway and the circumstances under which products manufactured using a change may be distributed.

Japan introduces another set of regulatory procedures. In a December 2025 presentation at the CMC Strategy Forum Japan, Ryosuke Kuribayashi, review director at Japan's Pharmaceuticals and Medical Devices Agency (PMDA), compared post-approval reporting categories in Japan, the United States, and the EU.¹² He also discussed trial approaches to reporting certain moderate-risk changes in Japan. The presentation, which expressed the author's views rather than an official PMDA position, illustrates ongoing efforts to refine post-approval change management but should not be interpreted as establishing finalized requirements for the proposed approaches.

For a manufacturer supplying several regions, a single process modification may require different regulatory classifications, supporting documentation, submissions, and implementation decisions. Even when regulators agree on the scientific principles used to evaluate the change, the company must address the requirements associated with each affected marketing authorization.

These differences can influence decisions about when to introduce improved processes, how to manage inventory during manufacturing transitions, and how to maintain supply across markets. A coordinated global change-control system can address the common technical assessment while identifying market-specific regulatory requirements before implementation.

Sterile manufacturing illustrates how internationally shared quality objectives can be addressed through distinct regulatory guidance frameworks.

The European Commission's revised EU GMP Annex 1, which generally entered into operation in August 2023, places significant emphasis on comprehensive contamination control.¹³ The annex requires manufacturers to develop a contamination control strategy (CCS) that identifies critical control points and evaluates the technical, procedural, organizational, and monitoring measures used to prevent contamination. The approach connects contamination prevention with quality risk management, facility and equipment design, personnel practices, validation, and ongoing monitoring.

In the United States, the FDA's guidance on sterile drug products produced by aseptic processing describes approaches manufacturers can use to satisfy applicable current GMP requirements under 21 CFR Parts 210 and 211.¹⁴ Both regulatory frameworks address contamination prevention and process control, although manufacturers must demonstrate that their procedures and documentation satisfy the expectations of each applicable authority.

A common contamination-control approach can provide a consistent technical foundation across manufacturing sites. Companies must still demonstrate that their control strategies and supporting evidence address the regulatory expectations applicable to their products and facilities. The opportunity lies in maintaining scientifically consistent manufacturing controls while accommodating differences in guidance structure and regulatory oversight.

Batch release provides a more direct example of how national and regional legal obligations can persist despite broadly aligned GMP expectations.

Within the EU, the Qualified Person (QP) framework establishes specific responsibilities for certifying medicinal product batches before their release for sale or supply. The QP performing final certification retains overall responsibility for ensuring that the batch has been manufactured in accordance with GMP and the applicable marketing authorization. This remains the case when different manufacturing stages occur at multiple sites.^15,16

The certification process also requires appropriate visibility into manufacturing and supply-chain information. EMA guidance addresses the documentation and traceability needed to support QP oversight, including information concerning suppliers and outsourced manufacturing activities.

The FDA's CGMP framework likewise establishes quality-unit responsibilities for batch release. Under 21 CFR 211.192, the quality control unit must review and approve drug product production and control records, including packaging and labeling records, to determine compliance with established procedures before a batch is released or distributed.¹⁷ This is a specific U.S. regulatory requirement, but it does not replicate the EU's statutory QP certification mechanism. Manufacturers supplying both markets must therefore distinguish the quality information supporting batch disposition from the separate legal responsibilities associated with release.¹⁸

Even within the EU, certain arrangements remain subject to national conditions. EMA guidance on remote QP certification explains that the practice may be permitted when accepted by the relevant national competent authority, which may impose additional requirements.¹⁹ Manufacturers and QPs must therefore confirm that any remote certification arrangements comply with applicable local requirements as well as EU GMP obligations.

For multinational manufacturers, these differences require clear assignment of release responsibilities. Common manufacturing records, quality assessments, and supply chain information can support multiple regulatory systems, but the organization must ensure that the appropriate certification and release requirements are fulfilled for each market.

Although national regulatory procedures remain distinct, international cooperation has demonstrated that certain oversight activities can be coordinated without establishing identical legislation.

MRAs allow participating regulatory authorities to rely on aspects of one another's GMP inspection systems under defined conditions. According to the EMA, these agreements can facilitate the exchange of inspection and quality-defect information, reduce duplicate inspections, and, where covered by the relevant agreement, waive certain batch-testing requirements for imported medicinal products.²⁰ Their scope depends on the participating authorities and the products or activities included.

The agreement between the FDA and EU offers an established example.²¹ The pharmaceutical GMP annex entered into force in November 2017, following efforts to assess participating inspectorates and establish mechanisms for exchanging inspection information. Recognition depends on evaluations of regulatory authorities' inspection capabilities rather than an assumption that common GMP guidance alone guarantees equivalent oversight.

The FDA published an assessment of the agreement's early operational impact in December 2019.²² Mark Abdoo, then the agency's associate commissioner for global policy and strategy, reported that EU authorities had conducted 29 inspections at FDA's request, while FDA inspectors had conducted 14 inspections at the request of EU authorities. More significantly, the FDA had deferred 157 inspections in the EU after reviewing inspection information supplied by its European counterparts.

The deferred inspections are particularly informative. Rather than proceeding automatically with planned inspections, the FDA used information from recognized regulatory partners to determine whether its own inspection activity was necessary. The figure demonstrates actual reliance on another authority's work, although it does not establish that every deferred inspection was permanently eliminated or provide a current cumulative total.

Regulatory reliance can reduce duplication and allow authorities to direct inspection resources toward facilities or risks warranting greater attention. However, the published FDA figures do not establish a corresponding dollar value for savings to pharmaceutical manufacturers.

The scope of these agreements remains limited. The FDA–EU MRA principally addresses routine surveillance inspections within the capabilities recognized under the agreement. Advanced therapy medicinal products, human blood, human plasma, human tissues and organs, and veterinary immunologicals are excluded. Vaccines for human use, plasma-derived pharmaceuticals, and investigational products have been identified for further consideration rather than being automatically covered by the arrangement. Certain recognized authorities also have specific limitations on the manufacturing activities included.

The FDA has established GMP inspection MRAs with Switzerland and the United Kingdom as well, extending reliance beyond its agreement with the EU. These arrangements provide additional mechanisms for cooperating with recognized inspectorates while retaining defined scopes and conditions.

Broader international initiatives seek to extend the benefits of cooperation to regulatory systems that may not participate in comprehensive bilateral recognition arrangements. The World Health Organization (WHO) has established good reliance principles encouraging authorities to make appropriate use of regulatory work performed by trusted counterparts while retaining responsibility for their own decisions.²³ WHO identifies reliance as a way to make better use of regulatory resources and strengthen oversight within individual jurisdictions.

Further international harmonization will depend partly on how consistently regulators implement existing standards and how effectively they recognize work performed by trusted authorities. For multinational manufacturers, the more immediate challenge is organizing quality and regulatory operations around common principles while accounting for requirements that remain market-specific.

A globally integrated pharmaceutical quality system can provide consistent standards for manufacturing controls, quality risk management, change evaluation, and documentation. That system must also identify where regional regulatory obligations affect the planning and execution of manufacturing activities.

Global change control provides a useful example. A manufacturer can use one technical process to evaluate the impact of a proposed modification on product quality, including the need for supporting studies, process validation, or changes to the control strategy. The regulatory assessment must then identify affected products and markets, determine applicable submission pathways, and establish when implementation may proceed in each jurisdiction.

Integrating these assessments early in change planning can help prevent regulatory requirements from becoming unexpected constraints after technical decisions have been made. It also provides a clearer basis for coordinating manufacturing schedules, documentation, inventory, and supply planning across markets.

Similar principles apply to inspection readiness. Consistent quality documentation and manufacturing records can support oversight by multiple authorities, provided manufacturers maintain clear mappings to applicable regulatory requirements. Information about previous inspections, corrective actions, and the status of manufacturing controls can be organized to facilitate interactions with different inspectorates, even when those authorities do not formally recognize one another's inspections.

Batch release also requires coordination between global quality processes and regional legal obligations. A manufacturer may rely on common manufacturing records and quality assessments while maintaining separate arrangements for QP certification, U.S. quality-unit responsibilities, and other applicable release requirements. Clear accountability becomes particularly important when manufacturing, testing, packaging, and release activities are distributed across multiple organizations or jurisdictions.

These approaches allow companies to standardize elements of pharmaceutical quality oversight that are genuinely common while retaining explicit control over requirements that cannot be treated interchangeably. They also provide a foundation for adapting to further regulatory convergence without repeatedly redesigning underlying quality processes.

From the regulatory perspective, closer alignment of post-approval change procedures remains an important opportunity. ICH Q12 provides common scientific principles, while the evolution of the EU variations framework demonstrates how regional procedures can continue to change. Greater consistency in change classification and the evidence required to support regulatory decisions could make global life cycle management more predictable.

Inspection cooperation offers another avenue for improvement. Existing MRAs demonstrate the value of assessing inspectorate capabilities, exchanging reliable information, and using the findings of trusted partners. Expanding such arrangements where appropriate could further reduce duplication, provided recognition remains supported by confidence in regulatory oversight and clearly defined agreement scopes.

Emerging manufacturing technologies create an additional opportunity to establish common expectations before substantially different regulatory approaches become entrenched. ICH Q13, which addresses continuous manufacturing of drug substances and drug products, provides shared scientific and regulatory considerations for developing, implementing, operating, and managing these processes throughout their life cycle. The FDA issued final guidance implementing Q13 in March 2023.²⁴

Continued cooperation on advanced manufacturing technologies could help authorities and manufacturers address regulatory questions earlier in development, reducing the need to reconcile divergent approaches as those technologies become more widely adopted.

Pharmaceutical manufacturers already operate within a substantially harmonized international foundation for GMP, but the legal and procedural systems governing compliance remain far from unified. ICH and PIC/S have helped establish widely shared technical expectations, while MRAs and other reliance arrangements have demonstrated that regulatory cooperation can reduce some duplicative oversight activities.

Different national and regional requirements nevertheless continue to govern how manufacturers report and implement changes, how authorities recognize inspections, and how medicinal product batches are certified and released. These obligations create complexity even when the underlying manufacturing quality standards are closely aligned.

Further progress will depend on narrowing the distance between international technical agreement and its practical implementation. More consistent regulatory procedures, broader use of trusted inspection findings, and coordinated approaches to emerging technologies could make global manufacturing oversight more predictable without eliminating legitimate national responsibilities.

The most useful measure of future GMP harmonization may therefore be the extent to which regulators and manufacturers can operate within interoperable systems, applying consistent quality principles, recognizing reliable regulatory work across borders, and reducing unnecessary duplication while maintaining effective oversight of pharmaceutical manufacturing.

1. “ICH Guideline Implementation.” International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Accessed 28 Oct. 2026.

2. “Introduction.” Pharmaceutical Inspection Co-operation Scheme. Accessed 28 Oct. 2026.

3. “Revision of PIC/S GMP Guide (PE 009-18).” Pharmaceutical Inspection Co-operation Scheme. 23 Sep. 2026.

4. “Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4).” Pharmaceutical Inspection Co-operation Scheme. 30 Jul. 2026.

5. “Frequently Asked Questions.” Pharmaceutical Inspection Co-operation Scheme. Accessed 28 Oct. 2026.

6. “ICH Guideline Q12 on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management – Step 5.” International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use / European Medicines Agency. 4 Mar. 2020.

7. “Note on EU Implementation of ICH Q12 (Guideline on Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management).” European Commission, Directorate-General for Health and Food Safety. 4 Mar. 2020.

8. “Guidance on the Application of the Revised Variations Framework.” European Medicines Agency. Accessed 28 Oct. 2026.

9. “Questions and Answers on Post Approval Change Management Protocols (PACMP) – Revision 1.” EMA/CHMP/QWP/586330/2010 Rev. 1. European Medicines Agency. 11 Dec. 2025.

10. “21 CFR § 314.70 — Supplements and Other Changes to an Approved NDA.” Electronic Code of Federal Regulations. Accessed 28 Oct. 2026.

11. “21 CFR § 601.12 — Changes to an Approved Application.” Electronic Code of Federal Regulations. Accessed 28 Oct. 2026.

12. Kuribayashi, Ryosuke. “Regulatory Updates and a Perspective on Biologics in Japan.” Pharmaceuticals and Medical Devices Agency. Presentation at CMC Strategy Forum Japan. 8 Dec. 2025.

13. “The Rules Governing Medicinal Products in the European Union, Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products.” European Commission. 22 Aug. 2022.

14. “Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice: Guidance for Industry.” U.S. Food and Drug Administration. Oct. 2004.

15. “EudraLex, Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 16: Certification by a Qualified Person and Batch Release.” European Commission. 12 Oct. 2015.

16. “Guidance on Good Manufacturing Practice and Good Distribution Practice: Questions and Answers.” European Medicines Agency. Accessed 28 Oct. 2026.

17. “21 CFR § 211.192 — Production Record Review.” Electronic Code of Federal Regulations. Accessed 28 Oct. 2026.

18. “EudraLex, Volume 4: EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 16: Certification by a Qualified Person and Batch Release.” European Commission. 12 Oct. 2015.

19. “Guidance on Good Manufacturing Practice and Good Distribution Practice: Questions and Answers.” European Medicines Agency. Accessed 28 Oct. 2026.

20. “Mutual Recognition Agreements (MRA).” European Medicines Agency. Accessed 28 Oct. 2026.

21. “European Union (EU) Mutual Recognition Agreement.” U.S. Food and Drug Administration. Accessed 28 Oct. 2026.

22. Abdoo, Mark. “Measuring the Impact of the Pharmaceutical Annex to the U.S./EU Mutual Recognition Agreement.” U.S. Food and Drug Administration. 6 Dec. 2019.

23. “Good Reliance Practices in the Regulation of Medical Products: High-Level Principles and Considerations.” WHO Technical Report Series. World Health Organization. 1033: 237–267 (2021).

24. “Q13 Continuous Manufacturing of Drug Substances and Drug Products: Guidance for Industry.” U.S. Food and Drug Administration. Mar. 2023.